Cost-effectiveness of Dalteparin vs Unfractionated Heparin for the Prevention of Venous Thromboembolism in Critically III Patients

Saved in:
Bibliographic Details
Published inJAMA : the journal of the American Medical Association Vol. 312; no. 20; pp. 2135 - 2145
Main Authors FOWLER, Robert A, MITTMANN, Nicole, ORMANIDHI, Orges, ARABI, Yaseen, QUSHMAQ, Ismael, ROCHA, Marcelo G, DODEK, Peter, MCINTYRE, Lauralyn, HALL, Richard, FERGUSON, Niall D, MEHTA, Sangeeta, MARSHALL, John C, GEERTS, William, DOIG, Christopher James, MUSCEDERE, John, JACKA, Michael J, KLINGER, James R, VLAHAKIS, Nicholas, ORFORD, Neil, SEPPELT, Ian, SKROBIK, Yoanna K, SUD, Sachin, CADE, John F, HEELS-ANSDELL, Diane, COOPER, Jamie, COOK, Deborah, GOULD, Michael K, GUYATT, Gordon, KRAHN, Murray, FINFER, Simon, PINTO, Ruxandra, CHAN, Brian
Format Journal Article
LanguageEnglish
Published Chicago, IL American Medical Association 2014
Subjects
Biological and medical sciences
General aspects
Medical sciences
Human
Unfractionated heparin
Medicine
Health economy
Antithrombotic agent
Low molecular weight heparin
Patient
Anticoagulant
Dalteparin sodium
Comparative study
Cost efficiency analysis
Online AccessGet full text

Cover

More Information
ISSN:0098-7484
1538-3598